A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted in many new therapies available for patients with advanced disease. Stratification of treatment by histologic and molecular subtype is recommended in order to obtain the greatest clinical benefit for patients while minimizing adverse effects of treatment. However, these advances in diagnosis and treatment of NSCLC have come at a financial cost. This review highlights the economic impact of screening for molecular abnormalities and targeted treatment for advanced NSCLC. Major determinants of cost are drug acquisition and molecular testing. As technologies advance, molecular testing costs may reduce. However, we must collaborate with payers and manufacturers to ensure that high drug costs do not limit patient accessibility to potentially beneficial treatment.
Graham, D. M., & Leighl, N. B. (2014). Economic impact of tissue testing and treatments of metastatic NSCLC in the era of personalized medicine. Frontiers in Oncology, 4(SEP). https://doi.org/10.3389/fonc.2014.00258